reason report
alpha readi roxa pivot data
bottom line updat ckd anemia model
increas price target stock
complet deep dive analysi pre-clin earli
clinic data commerci potenti hif class left
us feel posit potenti hif class overal
roxadustat particular expect roxadustat differenti
current anemia medicin cardiovascular safeti expect fibrogen
partner astrazeneca/astella report top-lin data least
seven nine outstand phase trial end
believ posit catalyst stock ahead
highli anticip pool mace analysi earli
analysi potenti outcom roxadustat cardiovascular
safeti endpoint mace defin approv
commerci potenti entir class view pool mace
analysi expect earli month upcom top-
line data disclosur analysi feedback medacorp
nephrologist suggest roxadustat like succeed
efficaci safeti non-inferior on-going trial addit
believ reason chanc roxadustat show superior
cardiovascular safeti epogen dialysi popul base
improv understand hif mechan exist phase ii
sale roxadustat estim fibrogen
record royalti profit share revenu expect
roxadustat receiv regulatori approv china japan
next month approv us eu like occur
upcom phase data posit appear
year lead time advantag us european market versu
nearest hif competitor could multi-year advantag china/
japan due compani regulatori partner strategi
base chang revenu forecast roxadustat
updat price target maintain outperform rate
stock believ investor may underestim
probabl roxadustat non-inferior epogen placebo
differ ckd popul price target suggest upsid
current stock price believ could realiz stepwis
earli
compani inform leerink partner llc research
revenu ep present
net debt total capit
pleas refer page import disclosur price chart analyst certif
rate outperform leader develop novel agent target fibrosi
hypoxia pathway treatment anemia fibrot diseas roxadustat first-in-class
hif hypoxia-induc factor prolyl hydroxylas phd inhibitor mimic bodi natur
respons hypoxia low oxygen condit shown larg phase program
involv nearli patient safe effect treat dialysis-depend dd
non-dialysi depend ndd chronic kidney diseas ckd consist medacorp key
opinion leader kol feedback think roxadustat potenti game changer
larg anemia market roxadustat current midst data readout
patient phase program around world key investor concern appear whether
upcom phase data show roxadustat non-inferior superior esa
cardiovascular outcom measur believ preponder evid suggest
roxadustat least non-inferior esa potenti even better take
uniqu develop approach china use green channel could potenti allow
compani gain access countri rapidli expand dialysi popul final
pamrevlumab connect tissu growth factor ctgf inhibitor head toward
phase develop idiopath pulmonari fibrosi pancreat cancer posit earli data
asset ad valu stock upsid potenti increas
probabl success opportun emerg fibrot diseas indic
introduc novel class valid mechan
roxadustat advanc medicin novel class oral anemia drug refer
hypoxia induc factor prolyl hydroxylas inhibitor current partner
astella astrazeneca akebia gsk bayer investig class molecul
variou stage phase develop hif pathway initi discov
close link endogen erythropoietin express tradit erythropoietin
stimul agent esa use improv hemoglobin level epogen/procrit epoetin
alfa aranesp darbepoetin alfa function mimick endogen erythropoietin
hormon secret healthi kidney signal bone marrow produc red
blood cell normal condit hif- subunit degrad prolyl hydroxylas enzym
halt gene transcript erythropoietin low oxygen environ hif- stabil
combin molecul drive transcript ultim result red blood cell
format bodi endogen erythropoiesi pathway roxadustat
develop design prevent degrad hif- result greater frequenc
gene transcript red blood cell format exhibit
exhibit drive product endogen erythropoietin
gupta et al american journal kidney diseas
anemia chronic kidney diseas patient caus insuffici red blood cell product
insuffici iron one shortcom esa stimul product
red blood cell bone marrow increas avail iron necessari
compon hemoglobin reason patient benefit sub-optimal
respons exogen erythropoietin administr despit increas red blood cell product
medicin
addit endogen epo stimul hif pathway import function
upregul iron avail product hemoglobin two mechan
upregul transferrin transport iron blood downregul hepcidin
protein prevent iron absorpt gi tract improv iron avail
develop hypothes medicin may effect esa treat
anemia chronic kidney diseas ckd seem plausibl sinc hif prolyl hydroxylas
inhibitor abl simultan stimul endogen epo product iron avail
effect product hemoglobin synthesi suggest therapeut effect
limit individu whose sole reason anem low endogen epo
believ limit esa treat ckd anemia illustr
requir frequent iron supplement evid posit effect iron
metabol respons efficaci esa rather esa treat anemia
increas erythropoietin alon despit sub-optimal iron avail mani patient fact
relev guidelin nephrologist stipul iron evalu prior begin esa treatment
regularli thereaft dialysis-depend patient intraven iron administ
frequent weekli usrd unit state renal data system report per-
patient-per-year direct cost intraven iron supplement roxadustat
abl show decreas requir iron supplement rel esa believ
would offer econom advantag would support premium price
proof concept establish multipl ckd trial sever develop
establish proof concept roxadustat eight phase ii studi non-dialysi
depend dialysis-depend ckd patient report base
promis similar improv efficaci better safeti partner embark
patient phase program roxadustat last studi
complet next month
roxadustat complet four phase ii studi non-dialysi depend ndd ckd popul
largest ndd phase ii trial subject stage ckd hemoglobin
g/dl random receiv one six dose schedul roxadustat
week assess hemoglobin respons g/dl g/dl week
across six cohort subject achiev primari endpoint median time
hemoglobin respons two month exhibit subject studi requir
exhibit roxadustat rais hemoglobin g/dl phase ii ndd studi
provenzano et al clinic journal american societi nephrolog
investig roxadustat efficaci convers mainten treatment dialysis-
depend ckd patient stabl epoetin alfa subject two-part studi
publish part trial subject initi random receiv six week
either roxadustat continu esa treatment assess mainten hemoglobin
defin hemoglobin at/abov baselin primari endpoint hemoglobin
mainten occur higher rate roxadustat compar epoetin alfa exhibit
lowest roxadustat arm met primari endpoint three higher dose cohort
subject achiev hemoglobin mainten versu subject epoetin alfa arm
sinc iv iron use allow requir dialysi patient take esa roxadustat
rel advantag epogen studi highlight rel advantag
esa iron metabol
exhibit roxadustat outperform epogen phase ii dd studi
provenzano et al american journal kidney diseas
part studi subject random one six roxadustat dose
schedul epoetin alfa week assess mainten hemoglobin g/dl
final four week intent treat popul pool roxadustat
cohort versu epoetin alfa treat subject achiev endpoint mean chang
hemoglobin similar g/dl group mean roxadustat dose hemoglobin
mainten establish mg/kg tiw
exhibit roxadustat solid line maintain higher hgb level epogen dash
provenzano et al american journal kidney diseas
roxadustat potenti establish near-term data disclosur
start partner began patient phase program roxadustat
dialysi depend non-dialysi depend ckd support regulatori approv around
world phase program consist seven studi ndd ckd nine studi dd ckd
patient seven studi enrol subject us six studi enrol subject europ two
studi china six studi japan result five dd two ndd studi
report far howev largest studi includ includ co-primari
endpoint major advers cardiac event mace expect read
end two largest phase trial alreadi report top-lin data alp
ndd dd
top-lin press releas astella subject alp studi septemb
indic roxadustat statist superior placebo improv hemoglobin
trial disclos addit detail efficaci result expect given
known lack hemoglobin respons placebo data least de-risk efficaci side
phase program non-dialysi popul
largest dd phase report data far chines studi subject end-
stage renal diseas share press releas data studi
dd ckd patient china earli press releas indic roxadustat achiev
primari endpoint non-inferior vs epoetin alfa also statist superior epoetin alfa
full analysi data along other de-risk efficaci compon
regulatori approv dialysi popul
second dd studi read astella report data japanes studi
may studi roxadustat non-inferior aranesp darbepoetin alfa maintain
hemoglobin level week dose astella press releas indic chang
hemoglobin roxadustat nearli ident chang aranesp vs
comfort met pre-specifi non-inferior margin g/dl
initi posit trial posit read-through remain studi expect
report end howev investor keen see result
two largest studi rocki olympu includ mace
along hemoglobin respons co-primari endpoint given accumul phase ii
phase data thu far investor unlik believ much risk remain efficaci
side particularli given low bar posit dd non-inferior margin ndd
set superior vs placebo ultim roxadustat abil prove least non-inferior
epogen placebo cardiovascular safeti dd ndd set determin
approv commerci potenti drug
four advanc phase studi support larg
pharma research develop dollar partner astella astrazeneca
akebia partner otsuka gsk bayer intern develop
hif program believ larg market potenti class drug support multipl
entrant howev often case competit therapeut categori like
major winner like first market posit roxadustat strong
efficaci profil demonstr multipl phase ii phase studi
believ broad clinic develop strategi confer advantag asset
rel peer
believ subtl differ efficaci and/or safeti like reveal
respect larg phase program time find difficult make cross-trial
comparison four asset given small size natur phase ii program
dose rang differ definit respons etc four phase ii program
efficaci improv hemoglobin appear gener similar four would
expect optim dose either agent suffici boost hemoglobin level similar extent
esa notic point differenti view dose schedul
consequ pharmacokinet profil four molecul exhibit roxadustat
longest serum half-lif four hour versu report half-liv hour
other roxadustat dose three time weekli tiw dialysi non-dialysi
patient dose daili phase studi review clinicaltri gov
indic akebia vadadustat studi daili tiw dose frequenc
gsk daprodustat bayer molidustat given daili
roxadustat dose tiw
view roxadustat tiw dose frequenc better suit competitor use
dialysi popul dose schedul align perfectli dialysi treatment
current esa administr schedul non-dialysi popul daili dose regimen may
prefer therefor follow-on could well-posit secur market share
segment succeed phase program medacorp feedback describ
end note suggest us real concern among nephrologist
complianc oral administ hif dose daili dialysi popul
exhibit roxadustat prolong serum half-lif allow optim dose
gupta et al american journal kidney diseas
analysi suggest roxadustat phase program largest
comprehens four late stage develop exhibit
fibrogen/astellas/astrazeneca enrol subject across phase studi
around globe enrol patient either akebia gsk bayer also
find roxadustat phase program broadest term geograph reach roxadustat
studi eight differ trial dedic sole patient china japan
wherea competitor mere enrol subject hand site within
largest multicent trial aim support global approv roxadustat program
comprehens term patient type within dialysi trial
investig use roxadustat incid dialysi patient mainten
switch esa within non-dialysi investig roxadustat studi
esa-nav experienc subject compar placebo aranesp
exhibit roxadustat phase program largest broadest
roxadustat phase readout come month akebia vadadustat set report
top-lin result gsk bayer least year behind akebia
expect four includ hemoglobin respons mace regulatori endpoint
respect program dialysi popul need show non-inferior
esa hemoglobin respons mace non-dialysi popul must
show superior hemoglobin respons placebo non-inferior cardiovascular outcom
roxadustat result expect year-end
least seven nine remain phase studi roxadustat set report top-lin data
year guid toward report pool mace analysi
studi enrol us eu patient earli compon trial
complet extern adjud process finish seven studi read
expect learn top-lin data hemoglobin respons gener safeti result
although mace co-primari endpoint rocki olympu believ
mace data reveal top-lin disclosur pool mace analysi earli
signific catalyst expect share experi volatil
around data disclosur time investor like price roxadustat
size phase program studi us studi europ studi ex-us/euestim phase completionroxadustat yet announc phase plan outsid japan fibrogen inc
long bumpi ride epogen co
mp first biopharmaceut compani success develop
erythropoiesi stimul agent recombin dna technolog epogen epoetin alfa
first approv treatment anemia relat chronic kidney diseas function
ident bodi endogen erythropoietin hormon lead increas red blood cell
format commerci epogen dialysi popul grant market
right epoetin alfa procrit non-dialysi patient subsidiari johnson johnson
op market epogen/procrit around world gener
peak year sale earli prior sever competit entrant heighten
alfa also approv fda five amino acid chang epoetin alfa result
substanti longer half-lif permit less frequent dose aranesp compar
predecessor conveni dose regimen aranesp import increas
penetr non-dialysi ckd popul cancer induc anemia dialysi type
dose schedul burden patient provid recent year roch
chugai major competit domin esa franchis roch epoetin
beta medicin neorecormon/epogin initi market europ longer-act
pegyl epoetin beta product mircera final allow roch enter us ckd market
exhibit launch biosimilar epoetin alfa medicin around world recent year
increas number esa market reduc profit
medicin manufactur countri china estim domest
esa manufactur control anemia market
exhibit epogen/procrit esa agent approv
black box unexpect cardiovascular risk curtail esa util sale
concern increas cardiovascular risk patient take esa medicin gain momentum
earli around time esa sale util peak level follow
public sever larg studi demonstr correl higher dose
esa mortal medic commun investig hypothesi sever random
prospect studi nh choir treat studi investig risk associ
activ titrat esa dose achiev normal hemoglobin level oppos
administ medicin standard dose three studi mortal cardiovascular
advers event risk increas titrat esa dose achiev normal hemoglobin level
compar lower hemoglobin target exhibit hazard ratio target normal
hemoglobin treatment induc harm nh choir
treat studi notabl higher risk all-caus mortal nh hr
choir hr significantli elev risk stroke treat hr addit
treat normal hemoglobin shown improv patient clinic symptom
qualiti life sever observ academ studi
exhibit nh choir treat chang pattern esa use forev
prior result choir treat physician routin treat ckd cancer patient
goal normal hemoglobin level even though often requir higher
recommend dose agent base find three larg studi
fda chang recommend use medicin result declin
number patient take esa well averag dose per patient year follow
revenu develop medicin flatten declin entir class greater
restrict place treatment guidelin adapt new inform
fda respond new safeti data includ black box warn increas
mortal cardiovascular event risk tumor progress risk entir class
initi black box specif indic hemoglobin maintain within defin rang
g/dl prior inclus common practic target hemoglobin goal
g/dl ckd patient fda move away recommend target hemoglobin
alon treatment guid hemoglobin level plu transfus risk final label updat
recommend esa use lowest dose suffici reduc need red
blood cell transfus exhibit definit leav much interpret provid
insur greater power determin appropri esa use non-dialysi
ckd popul result much lower util subsequ year physician
advis reduc interrupt dose hemoglobin approach g/dl dialysis-depend
patient g/dl non-dialysi depend ckd patient wherea hemoglobin target
previous g/dl popul
exhibit black box label esa
result chang recommend class medicin use
overal util entir class decreas approxim half past year
averag hemoglobin level dialysi patient take epoetin alfa
averag weekli dose reach high unit follow product label
chang fda mean hemoglobin level averag weekli dose declin
unit respect exhibit declin util also result
substanti sale declin entir class medicin us europ peak sale
declin earli exhibit
exhibit mean esa dose hemoglobin target come consider
exhibit us/eu sale esa decreas revis fda guidanc
hif inhibitor immedi advantag tradit esa oral dose
big question still whether greater fewer document risk
associ esa never fulli explain whether risk associ
drug artifici produc erythropoietin drug exposur higher normal rang
erythropoietin exposur drug effect normal supra-norm hb patient associ
patholog advers event attribut drug like free
associ elev exposur erythropoietin also like
free reduc risk associ hb rise hb
level effect like effect esa
roxadustat benefit epo resist
estim chronic kidney diseas patient consid resist
hyporespond esa medicin ckd relat anemia result either intrins
kidney damag lack epo product low iron avail insuffici hemoglobin synthesi
system inflamm decreas iron avail logic esa alon would
benefit entir popul studi indic low iron satur
marker inflamm crp predictor resist esa link make
sens us sinc multipl input involv make oxygen avail tissu
includ hemoglobin product dial erythropoietin expect
work mani patient lack suffici red blood cell other may ever achiev adequ
benefit via mechan alon even esa dose increas beyond recommend level
iron supplement given
given mechan roxadustat address red blood cell hemoglobin synthesi
natur expect roxadustat effect broader rang individu esa would
includ may mount hemoglobin respons esa due low iron level
underli inflamm approxim ckd patient elev inflammatori
marker well-associ lower hemoglobin respons esa link convers
public phase ii roxadustat trial indic hemoglobin respons occur
independ degre baselin inflammatori marker like view
mechan esa resist ckd patient relat iron defici and/or
underli inflamm may address
roxadustat achiev hemoglobin respons normal level endogen
etiolog increas cardiovascular risk esa still uncertain mani suggest
secondari either increas hemoglobin level increas erythropoietin level
blood first potenti etiolog would least partial resolv fda revis
guidanc lower hemoglobin target treat ckd anemia still possibl higher
still sub-norm hemoglobin level may harm ckd patient howev believ
scenario less like true higher physiolog level erythropoietin induc
esa therefor like culprit view compon specif address
encourag data multipl hif studi demonstr strong hemoglobin
respons maintain near normal rang endogen erythropoietin level blood
normal rang erythropoietin healthi patient gener less mu/ml
previou studi shown low oxygen condit endogen erythropoietin
concentr increas transient factor mu/ml link howev
even hypox condit human erythropoietin level return slightli elev rang
within short time exposur persist high level suggest us
human bodi may natur protect mechan avoid extrem high level
erythropoietin long term
publish data roxadustat phase ii program dialysi patient compar level
serum erythropoietin follow epogen roxadustat administr exhibit studi
mean peak erythropoietin level follow epogen use mu/ml peak level
roxadustat mu/ml studi roxadustat produc statist superior
chang hemoglobin versu epogen develop shown
similar modest increas serum erythropoietin follow administr prove hif
class abl improv hemoglobin measur substanti lower level epo
exhibit normal increas erythropoietin roxadustat versu esa
provenzano et al american journal kidney diseas
believ cardiovascular event associ esa use like due persist
elev level erythropoietin blood due elev hemoglobin origin
choir studi subject random higher lower target hemoglobin epogen dose
titrat order achiev object outcom choir show
higher rate mace higher hemoglobin group hr
post-hoc analysi choir studi publish investig attempt
answer question divid subject respond non-respond categori base
initi hemoglobin respons treatment month base stratif subject
respond arm would higher hemoglobin level lower epogen dose requir
non-respond level would lower hemoglobin epogen dose titrat
upward subsequ follow period investig post-hoc analysi found
subject respond well esa initi significantli lower mace event rate
three-year period despit higher hemoglobin level throughout period data
suggest increas cardiovascular event associ higher dose epogen
caus higher hemoglobin level exhibit
exhibit mace associ esa dose requir hgb level
medacorp feedback highlight complex esa histori
untap potenti ckd anemia
conduct analysi spoke sever medacorp nephrologist well director
dialysi center current ckd anemia market opportun
indic physician spoke came larg academ center well larg
small commun practic across east coast mid-west unit state overal physician
describ current state anemia manag frustrat open new entrant
approach gener nephrolog commun seem cautiou optim
prove safer esa howev seem excit novel medicin
could work better hard treat patient nephrologist valu potenti oral
administr other appreci nuanc differ iron metabol
inflammatori marker esa
honest belief time normal hemoglobin better
across board physician substanti reduc esa use past
five ten year follow result treat prior studi public one physician
note honest belief time normal hemoglobin better anoth physician
said use give unit epogen per treatment resist patient
doesnt allow dose receiv consist feedback
physician larg major dialysis-depend patient receiv esa least
year well regular intraven iron supplement ndd popul
physician treat patient baselin hemoglobin
g/dl payer restrict treatment near-term risk transfus adequ
iron store medacorp feedback suggest looser restrict use anemia
medicin ndd-ckd popul could result anywher growth
patient treatment despit admiss overli aggress treatment approach
past one physician state person ever felt respons cardiovascular event
procrit
use make per year epogen procrit break even
physician agreement cost main driver esa choic
practic prior implement bundl reimburs system dialysi care
esa profit center dialysi center size sinc implement
bundl esa brand renal medicin sensipar cinacalcet eat
directli profit margin capit payment practic incentiv use less
nephrologist run larg suburban dialysi practic told us clinic use make
sizeabl profit administ epogen struggl lose money
medicin one nephrologist medic director half dozen dialysi facil indic
group recent switch epogen mircera order save per-patient-p
treatment state esa cost per-patient-p treatment
per patient annual addit cost iron per year
overhead expens relat iron esa administr difficult quantifi modestli
biggest excit better safeti similar slightli better efficaci
physician spoke mix term excit hif class note
enthusiasm nephrolog commun wax wane relat proxim new
data disclosur consist wall street expect nephrologist believ safeti
profil medicin import disclosur upcom dataset
ask whether oral conveni alon would meaning differenti safeti profil
shown equival esa one physician note happen disappoint
would physician told us ident safeti profil inject esa would
result switch hand dialysi patient mostli esa
hyporespond howev feedback suggest hyporespond popul
move target may easili captur specif cross-sect time
hyporespond may make dialysi patient popul chang
cours year individu undergo surgeri progress medic
comorbid lend suscept esa resist
show numer benefit mace versu inject esa one physician note
wouldnt switch dialysi patient oral anoth nephrologist state
superior cardiovascular profil versu esa would neglig use clearli
pool mace analysi roxadustat phase program defin moment
prospect entir class
size non-dialysi ckd opportun
physician spoke manag supervis manag non-dialysi
ckd patient respect practic mostli ckd stage state mani
two-third ndd patient anem howev necessarili mean
candid treatment due restrict esa use ndd popul probe
percentag patient symptomat hemoglobin g/dl answer
rang total ckd popul major elig patient
current manag longer-act inject esa aranesp
physician less cost-consci ndd ckd popul sinc coverag insur
compani respons receiv mix feedback conveni oral hif would
offer compar inject agent ckd popul physician state subcutan
iv administr substanti hindranc esa use popul howev also
vari practic practic assum ident profil esa
mani ckd patient would switch oral hif depend practic
argument high rate switch patient dont mind self-inject
home sick patient alreadi come offic everi week anyway
receiv inject visit worri ensur complianc oral medicin
taken home nephrologist state greater ckd patient drive
medic facil inject suggest oral conveni alon would signific
driver uptak
non-risk adjust
new ckd market model contain three scenario analys regard safeti profil
rel esa placebo use weight blend three possibl
outcom drive model
scenario forecast assum prove non-inferior esa
placebo mace/cv safeti scenario better cv safeti profil esa
non-inferior placebo scenario better cv safeti profil vs
esa placebo scenario weight current model three
assum shown non-inferior esa placebo peak hif
penetr dialysi depend popul hyporespond wherea
superior safeti profil versu esa dialysi patient switch
esa class medicin given import cv mortal risk set
non-dialysi popul non-inferior placebo estim
patient receiv hif late number increas
superior cardiovascular safeti profil addit believ ndd treatment market
expand beyond patient current anemia treatment show
believ roxadustat retain largest share global hif market given first mover
advantag strong big pharma partnership geographi specif forecast
roxadustat retain long-term share us eu share china
scenario weight annual cost roxadustat us dialysi popul
non-dialysi popul geographi forecast consider lower
forecast risk-adjust global sale roxadustat estim
record royalti profit share revenu exhibit probabl
success geographi indic non-risk adjust
global sale roxadustat record revenu
exhibit forecast risk adjust sale roxadustat
increas pt ahead upcom data disclosur
price target updat model increas previous result
chang roxadustat revenu forecast describ forecast initi
launch roxadustat japan china us/eu launch begin
addit updat roxadustat forecast includ near-term mileston
partner astrazeneca expect approv roxadustat china year
regulatori file approv mileston total progress us eu
japan current potenti regulatori mileston outstand us
eu alon believ realiz next two year believ investor
underestim likelihood mileston achiev reason revenu
forecast consider recent consensu estim near term forecast total
revenu come roxadustat royalties/profit share pamrevlumab sale
without major adjust oper expens forecast dilut ep
estim increas versu previous dcf valuat includ
discount rate cash flow termin growth rate thereaft
termin valu repres total npv includ compani
estim year-end cash balanc price target rate fibrogen
price target base dcf methodolog includ
probability-weight roxadustat royalti mileston payment astella eu japan
azn us row roxadustat profit-shar azn china assum
probabl success po dialysis-depend non-dialysi depend chronic
kidney diseas ckd indic variou geographi current model po
pamrevlumab idiopath pulmonari fibrosi ipf pancreat cancer assum
discount rate believ appropri given probability-weight sale
clinic risk includ abil roxadustat show statist signific improv
clinic relev trend toward improv cardiovascular cv outcom versu
erythropoietin-stimul agent esa phase dialysi trial placebo phase
unknown safeti issu associ phd inhibit hif stabil
clinic regulatori risk associ bring new class market variou
territori particularli china
uncertain size potenti anemia market particularli outsid dialysi set
unknown reimburs landscap us regard inclus roxadustat cmss
pamrevlumab safeti signal underwhelm result phase trial ipf pancreat
manufactur develop setback delay pamrevlumab compar
dialysi depend ckdnumber us hemodialysi annual requir treatment requir treatment receiv receiv hif- patient receiv esa patient receiv hif hd- number us home dialysi requir treatment receiv receiv hif- patient receiv esa home patient receiv hif home dialysis- total us dialysi patient hif-ph inhibitor- roxadustat patient roxadustat- average month treatment- total patient-month roxadustat- monthli cost us dialysi roxadustat sale pos-adj us dialysi roxadustat sale fibrogen inc
non-dialysi depend ckd stage non-dialysi ckd stage treat treat clinic relev treat treat ckd care treat receiv receiv patient receiv patient receiv hif- total ndd ckd patient hif- roxadustat- average month treatment- total patient-month roxadustat- monthli cost us ndd roxadustat sale pos-adj us ndd ckd roxadustat sale fibrogen inc
collabor servic revenu
revenu
revenu
revenu
interest expens net
total interest net
incom loss incom tax
provis benefit incom tax
enterpris valu termin valu
million except ep
free net cash oper activ
discount period one year today
incur yet
total npv cash flow tv
balanc
estim cash balanc per share
leerink partner compani report
